AdComm – Talk Bio

FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC

9 months ago talkbio0Tagged AdComm, AstraZeneca, Imfinzi, Immune Checkpoint Inhibitors, Immunologic Adjuvants, Neoadjuvant Chemotherapy, Non-Small Cell Lung Carcinoma, Overtreatment, perioperative, Single Agent Therapy, United States Food and Drug Administration

AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy

FDA Requests Additional Study on AstraZeneca’s Imfinzi for Lung Cancer Treatment

9 months ago talkbio0Tagged AdComm, AstraZeneca, Imfinzi, Malignant neoplasm of lung, Surgery specialty, United States Food and Drug Administration

FDA, AstraZeneca, Imfinzi, Lung Cancer, Surgery, Adcomm

ICER Raises Concerns Over Uncertainties in Lykos MDMA Clinical Trials Ahead of FDA Advisory Committee Meeting

11 months ago talkbio0Tagged AdComm, Advisory Committees, Clinical Trials, CREM gene, Lykos ', Midomafetamine, Uncertainty, United States Food and Drug Administration

ICER, Lykos, MDMA, clinical trials, uncertainties, FDA, AdComm, advisory committee meeting